Highlights Avacta Group Plc

Stocks

AVCT

GB00BYYW9G87

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 16:35:04 15/07/2026 BST			5-day change	1st Jan Change
69.00 ^GBX	0.00%		-2.13%	+18.97%

07-09	Avacta appoints "seasoned" new deputy chair	AN
07-09	Avacta Group Settles Accelerated Payment Under Convertible Bond	MT

Highlights

07-09	Avacta appoints "seasoned" new deputy chair	AN
06-25	Avacta Therapeutics Reaches Study Design Terms With US FDA for Salivary Gland Cancer Therapy	MT
06-25	Avacta Therapeutics Announces U.S. FDA Agreement on Pivotal Trial Design for AVA6000 in Patients with Salivary Gland Cancer	CI
06-22	Avacta hails "strong progress" in first half of 2026	AN
06-05	Avacta Therapeutics Raises GBP9 Million from Share Issue	MT
06-01	Avacta Therapeutics Presents Updated Clinical Data for Ava6000 in Salivary Gland Cancers At Asco 2026	CI
05-19	Avacta Group annual loss widens as cancer treatment trial results loom	AN
05-19	Avacta Therapeutics reports group revenues of £6.31 million for year ended December 31, 2025	RE
05-19	Avacta Group continues to explores multiple commercial opportunities with strategic partners	RE
05-19	Avacta Group Plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-06	Avacta Therapeutics Presents New Comparisons Of Pre\|CISION Payload Release Versus Approved ADCs And AVA6207 Dual Payload Delivery	CI
04-21	Avacta Therapeutics Presents Favorable Data for AVA6103 and Showcases Dual Payload pre\|CISION Platform At AACR 2026	CI
04-09	Avacta hails "important milestones" in start of "transformative" year	AN
03-31	Avacta Therapeutics Announces First Patient Treated In Phase 1 Focus-01 Trial Of FAP-Exd	CI
03-16	Avacta Group announces phase 1 study opening for AVA6103	RE
02-24	Avacta hails new data supporting proprietary preCision platform	AN
02-24	Avacta's pre\|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis	CI
02-03	Avacta Therapeutics Announces Two Key Clinical Updates to its Faridoxorubicin Clinical Program	CI
01-21	Avacta Therapeutics Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug Application for the Second Pre\|Cision® Medicine, Fap-Exatecan	CI
01-21	EARNINGS AND TRADING: Kenmare meets guidance, plans to lower costs	AN
01-21	Avacta announces US FDA clearance of the investigational new drug application for the second pre\|CISION medicine, FAP-Exatecan	RE
01-21	Avacta Therapeutics Wins US FDA Nod to Start Early-stage Trial of Cancer Drug FAP-Exd	MT
12-18	Avacta Reports New Pharmacology Data for Fap-Exd	CI
12-17	Avacta Therapeutics Announces Faridoxorubicin Phase 1B Cohort Demonstrates Clinically Meaningful Tumor Shailage in Patients with Salivary Metals Cancer	CI
25/10/25	Avacta Presents First Preclinical Data from Dual Payload Pre\|Cision® Medicines At the 2025 Aacr-Nci-Eortc International Conference on Molecular Targets	CI